WO2004008139A1 - Agent absorbant de diagnostic et article absorbant - Google Patents

Agent absorbant de diagnostic et article absorbant Download PDF

Info

Publication number
WO2004008139A1
WO2004008139A1 PCT/JP2003/008814 JP0308814W WO2004008139A1 WO 2004008139 A1 WO2004008139 A1 WO 2004008139A1 JP 0308814 W JP0308814 W JP 0308814W WO 2004008139 A1 WO2004008139 A1 WO 2004008139A1
Authority
WO
WIPO (PCT)
Prior art keywords
absorbent
water
diagnostic
resin
diagnostic agent
Prior art date
Application number
PCT/JP2003/008814
Other languages
English (en)
Japanese (ja)
Inventor
Hiroaki Maeda
Koji Kawaguchi
Hiroshi Itayama
Original Assignee
Sanyo Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanyo Chemical Industries, Ltd. filed Critical Sanyo Chemical Industries, Ltd.
Publication of WO2004008139A1 publication Critical patent/WO2004008139A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin

Definitions

  • the present invention relates to an absorbent material for diagnostic use for animals or humans, and more particularly, to an absorbent material, an absorbent sheet and the like which can be used for medical examinations, disease diagnoses and pregnancy tests between animals or humans.
  • the present invention relates to a diagnostic absorbent article used. Background art
  • a test material for urinalysis comprising a water-absorbent resin having a water absorption of 10 to 550 g per 10 g containing a urine test agent (Japanese Patent Laid-Open No. 11-295306).
  • a urine test diaper characterized by impregnating the inner surface of a diaper with a reaction reagent that changes color according to the components in the urine (Japanese Patent Application Laid-Open No. 200-289845) has been proposed. .
  • An object of the present invention is to provide a diagnostic absorbent that is excellent in persistence of color formation.
  • Another object of the present invention is to provide a diagnostic absorbent having a high coloring speed.
  • a further object of the present invention is to provide a diagnostic absorbent excellent in chronological stability (stability of diagnostic reagent).
  • Still another object of the present invention is to provide a diagnostic absorbent capable of diagnosing cancer.
  • Still another object of the present invention is to provide an absorbent sheet for diagnosis and an absorbent article having excellent persistence of coloring. Still another object of the present invention is to provide a diagnostic absorber and an absorbent article having a high coloring speed. Disclosure of the invention
  • the above and other objects of the present invention are the first embodiment of the present invention, which is a water-absorbent resin (A) (hereinafter also referred to as (A)) and a diagnostic agent (M) (hereinafter also referred to as (M)) And (A) having at least 60 times the water-absorbing ability.
  • A water-absorbent resin
  • M diagnostic agent
  • Another object of the present invention described above and below is a second embodiment of the present invention, comprising a water-absorbent resin (A) and a diagnostic agent (M), wherein (A) is an aliphatic unsaturated monocarboxylic acid.
  • One or more monomers (al) selected from the group consisting of amides, alkylene oxyside adducts of aliphatically unsaturated monocarboxylic acids, and their alkylated or alkyl etherified compounds, and optionally More than one kind of monomer (a 2) selected from the group consisting of more unsaturated anionic monomers, unsaturated cationic monomers and their salts, is contained as a constituent monomer.
  • a diagnostic absorbent characterized by having an acid or base equivalent of not more than 2 milliequivalents Zg determined by neutralization titration of H4-9.
  • Another object of the present invention described above and below is a third embodiment of the present invention, wherein at least 40% by weight of the water-absorbent resin (A) and 25 ppm by weight based on the weight of (A). 2. 5% of diagnostic agent (M), (M) supported on a support or coated with a water-soluble or water-disintegrable coating material, (A) supported or coated (M) Diagnostic absorbers, which are obtained by mixing
  • Another object of the present invention described above and below is a fourth embodiment of the present invention, wherein a water-absorbent resin (A) and a diagnostic agent for antigen-antibody reaction (M 0) (hereinafter referred to as (M 0)) ), which can be achieved by a diagnostic absorbent.
  • A water-absorbent resin
  • M 0 diagnostic agent for antigen-antibody reaction
  • a diagnostic absorbent sheet having the following (1) or (2) and a BZF separation layer (C):
  • FIG. 1 is a diagram schematically showing a cross section of urine U and a part of a diagnostic absorbent sheet of the present invention.
  • AL is a water absorbing resin layer
  • B 1 is a layer carrying a labeled antibody
  • C 1 is a B / F separation layer.
  • FIG. 2 is a diagram schematically showing a cross section of a part of an absorbent sheet in which urine U has penetrated into the AL layer and the B1 layer.
  • FIG. 3 is a diagram schematically showing a cross section of a part of the absorbent sheet in which urine U has penetrated to reach the B / F separation layer C 1.
  • FIGS. 4 to 6 are diagrams schematically showing a part of the cross section of the absorbent sheet of the present invention.
  • ⁇ F is a front film
  • C 2 is a BZF separation layer
  • D is a color former layer
  • U F is a back film.
  • P in Fig. 6 is a hole.
  • FIG. 7 is a cross-sectional view of a part of the absorbent sheet prepared in Examples 5 and 6.
  • the water-absorbent resin (A) that can be used in the present invention has a weight of 10 to 2,0. It is a hydrophilic cross-linked polymer that can absorb 100 times water.
  • polymers are usually hydrophilic groups such as carboxylic acid (salt) groups (ie, carboxyl and / or carboxylate groups), sulfonate (salt) groups, and phosphoric acid (salt) groups. It has a tertiary amino group, a quaternary ammonium base, a hydroxyl group or a polyethylene oxide group.
  • salt carboxylic acid
  • salt carboxyl and / or carboxylate groups
  • sulfonate (salt) groups phosphoric acid (salt) groups. It has a tertiary amino group, a quaternary ammonium base, a hydroxyl group or a polyethylene oxide group.
  • Preferable (A) includes the following.
  • a water-absorbent resin (A 1) capable of absorbing water 100 to 1,000 times as much as water, and an aliphatic unsaturated monocarboxylic acid Or an alkylene oxide adduct (all) (hereinafter, also referred to as (al1)) of the above, or an alkylated or alkyl ether amide (al2) (hereinafter, (al2) ))
  • A1 capable of absorbing water 100 to 1,000 times as much as water
  • monomers (a1) hereinafter also referred to as (a1)
  • a2 selected from the group consisting of saturated phosphoric acids and their salts are defined as constituent monomers.
  • (A1) a starch-acrylic acid (salt) graft crosslinked copolymer and a crosslinked polyacrylic acid (salt) are preferred.
  • (A1) has the advantage that the color development duration after the color development of the diagnostic agent is long.
  • Water absorption can be measured by the following method:
  • (A 1) is added to a tea bag of known weight (specified in JIS, K7223) with a size of 20 cm in length and 10 cm in width made of nylon mesh of 250 mesh. Add 2 g and immerse in 500 mL of deionized water. After 5 minutes, remove the tea bag and weigh it to determine the weight of water absorbed. Calculate the water absorption capacity from the following formula.
  • Water absorption capacity (times) [weight of absorbed water (g)] no 0.2 (g) (1) For example, if it can absorb 60 times its own weight of water, its water absorption capacity is 60 times.
  • (A1) preferably has an absorption rate of less than 80 seconds, especially less than 70 seconds. It is preferred that the absorption rate be less than 80 seconds, since the time from the start of absorption of the body fluid to the development of the diagnostic agent is short.
  • the absorption rate can be measured by the following measuring method:
  • a 1 is preferably 8 to 20 g Z g or more, especially 10 to 18 g Z g, 40 g Z cm 2 absorption under load for sheet and paper use applications Quantity (hereinafter abbreviated as Ab-L). If A b — L is 8 to 20 g Z g, problems such as liquid return rarely occur. A b —L can be measured by the method described in US Pat. No. 6,156,678.
  • (all) is an amide of an aliphatic unsaturated monocarboxylic acid (having 3 to 5 carbon atoms, hereinafter abbreviated as C).
  • C an aliphatic unsaturated monocarboxylic acid
  • the alkyl (Cl-4) diamide of (a11) [mono or dimethyl (meth) acrylyl amide, monoisopropyl (meta) ata linoleamide Etc.), and (a11) alkyl (C1-4) ether compound [ethylenoxide of (meth) atalylic acid with 1 to 100 moles Methyl etherified product of the additive, etc.].
  • examples of the unsaturated anionic monomer include unsaturated carboxylic acids, unsaturated sulfonic acids, unsaturated phosphoric acids and salts thereof, and the following are exemplified. .
  • the unsaturated carboxylic acids include the above-mentioned aliphatic unsaturated monocarboxylic acids, C 9 to 12 aromatic monocarboxylic acids [such as cinnamic acid and vinyl benzoate] and C 4 to 12 unsaturated dicarboxylic acids. [Maleic acid, fumaric acid, itaconic acid, aconitic acid, etc.].
  • Unsaturated sulfonic acids include alkene (C 2-6) sulfonic acid [such as vinyl sulfonic acid and (meth) aryl sulfonic acid], unsaturated aromatic (C 6-18) sulfonic acid (styrene sulfonic acid and ⁇ —Anolecenyl and alkyl (C 1-18) alkenyl esters of methyl styrene sulphonic acid, etc., and sulfocarboxylic acids (such as monosulfoalkanoic acid and snolephoconodic acid) [methyl vinyl, propyl (meta) aryl and Stearyl (meta) arylsulfosuccinate and (meta) arylsulfophosphate, etc., sulfo (hydroxy) alkyl (C2-6) (meta) atalylate and equivalent ( (Meta) Acrylylamide [Sulfoethyl and
  • Unsaturated phosphoric acids include (meta) atalyloyloxyalkyl (C2-24) mono- and diphosphates, [2— (meta) atalyloyloxyxethyl phosphate and Hue-Lu 2 — (meta) Atari Loiro Kishechyl phosphate etc.].
  • These salts include alkali metals (sodium, potassium and lithium). ), Alkaline earth metal (such as calcium and magnesium) salts, ammonium salts, organic amines (such as dimethylamine, trimethylamine, jetanolamine, triethanolamine), and quaternary salts Ammonia (such as tetramethylammonium) and the like.
  • unsaturated cationic monomers and their salts include:
  • (A 2) has an acid or base equivalent of less than 2 milliequivalents, preferably less than 1 milliequivalent Zg, as determined by neutralization titration at pH 4-9.
  • the diagnostic accuracy of the diagnostic agent (M), particularly the pH diagnostic agent (Ml) and the protein diagnostic agent (M2) described below is improved.
  • the acid or base equivalent of pH 4-9 can be measured as follows.
  • a 0.5 g sample of the water-absorbing resin is precisely weighed, and 100 mL of ion-exchanged water is added, followed by stirring for 30 minutes. Thereafter, 3% (hereinafter, unless otherwise specified,% represents% by weight) of an aqueous hydrogen chloride solution is added dropwise, and the pH is adjusted to 3 to 4.
  • Titrate with an NZ10NaOH aqueous solution using a potentiometric titrator read the titration ml number from pH4 to pH9, and calculate by the following formula (2).
  • Shiino preferred among (A 2) is 9 0-1 0 0 mole 0/0, especially 1 0 0 mole 0 / o units of (a 1), 0 to: 1 0 mole 0 /. , Especially 0 mol 0 /. (A2) and 0.01 to 3 mol% of the unit of the crosslinkable monomer (b).
  • (A 1) and when used in combination with (a 2), (a 1 ) 9 0 to 9 9 mol 0/0, the (a 2):! Rere Shi preferred is to 1 0 mol 0/0.
  • the crosslinkable monomer (b) is a compound having 2 to 4 or more functional groups capable of reacting with (a1) or (a2), and is a bis (meth) acrylamide or poly (meth) acrylamide. All di or polyunsaturated carboxylic esters, and polyol di or poly (meth) aryl ethers, and US Pat. No. 5,728,792 The compounds described are exemplified.
  • the water absorption capacity of (A 2) (measuring method is the same as that of (A 1)) is preferably 10 to 1000 times, more preferably 15 to 800 times.
  • the shape of (A) may be granular (spherical, granular, crushed, etc.), needle-like, flake-like, block-like, agglomerated form in which granular primary particles are fused together, and form-like. In particular, they are granular, needle-like, flaky and agglomerated.
  • the preferred size is that when the absorbent described below is used as cat litter, a particle size of 90% or more of (A) is preferable. :! ⁇ 850im, especially 3 ⁇ 500 ⁇ . This range is preferable because the absorption rate is particularly high.
  • ( ⁇ ) is preferably 38 to 118 ⁇ . In particular, it is 63-10000. If it is more than 38 ⁇ , gel blockage is less likely to be generated in the sheet when it comes into contact with an aqueous solution, and the absorption rate is improved. If it is not more than 118 ⁇ m, the surface area per volume of the absorbing material does not become small, and the absorbing speed tends to be high.
  • the size of the granular or agglomerated (A) was measured using a rotary test sieve shaker and a sieve specified in JISZ8801-2000.
  • the method can be performed according to the method described in the “Chemical” Engineers ”Handbook, 6th Edition (Mac Glow Hinole Book, Kannony, pp. 1984-21, page 21). Is based on this method.
  • the average particle size (weight average particle size, hereinafter abbreviated as Dav) is used as (A) for absorbent articles for humans (diapers, urine collection pads, etc.).
  • the water-absorbent resin having a smaller Dav ( ⁇ ′) (hereinafter also referred to as ( ⁇ ′)) preferably has a Dav of 50 to 400 m, particularly 100 to 350 m, It mainly contributes to the absorption rate. If it is 50 m or more, gel blocking is unlikely to occur, and if it is 40 ⁇ m or less, the surface area increases and the absorption rate tends to improve.
  • the water-absorbent resin with a large Dav ( ⁇ '') (also referred to as ( ⁇ '')) is preferably 410-750 ⁇ , especially 450-650 ⁇ Dav Having. If it is 410 ⁇ m or more, the return of water after water absorption tends to be small, and if it is 75 ⁇ m or less, it is easy to exhibit sufficient water absorption capacity.
  • the weight ratio of (A ′) :( ⁇ ′ ′) is usually (3: 7) to (7: 3), preferably (4: 6) to (6: 4).
  • Water-soluble inorganic salt based on the weight of (ii) is preferably 2% or less, more preferably 1% or less, and especially 0.3% or less, for the purpose of maintaining its properties over time. It is.
  • the inorganic salts include catalyst residues [sulfate (sodium sulfate, calcium sulfate) and sulfite (sodium sulfite, calcium sulfite)], and other inorganic salts (salts). , Calcium chloride, magnesium chloride, etc.).
  • the inorganic salt content can be measured as follows.
  • (M) includes a qualitative or quantitative amount of the component to be detected in a body fluid (urine or blood), or a diagnostic agent that diagnoses by measuring a characteristic value of urine.
  • the "diagnostic agent” includes a part or all of the reagents involved in the diagnosis, that is, a compound that reacts with a component in a body fluid, and, if necessary, a labeling substance or a coloring agent. included.
  • (M) includes the following.
  • pH diagnostic agent For example, methyl red Z bromthymol blue (BTB) (in the following, / represents a combination).
  • Protein diagnostics (M 2) For example, tetrabromphenol blue (TB PB) / Nouchenic acid dihydrogen potassium (for measuring albumin content).
  • Glucose diagnostics (M 3) (hereinafter also referred to as (M 3)): For example, glucose oxidase peroxidase Z color former (carboxylate, o-tridin, 3-amino-6-c) Roll 9-dimethylaminopropylcarbazol hydrochloride, 2,7-diaminofluorin dihydrochloride or N- (3-sulfopropyl) -1,3,3 ', 5,5'-tetramethylbenzidine Li).
  • Occult blood diagnostic agents For example, tamenyl hydroperoxydono o-triidine, citrate buffer 2,5-dimethylhexane 1,2,5—dihydrobaroxydotetramethylbenzidine, tamene hydroperoxide / Tetra methylbenzidine hydrochloride.
  • Pyrirubin diagnostics for example, 2,4-dichloroaniline, 2,6-dichlorobenzeneazoniummute trafluoroborate, or 2—trifluorobenzenebenzenediazoumute Borate.
  • Perobilinogen diagnostic agent (M 6): For example, p-dimethylaminobenzaldehyde, 4-methoxybenzenediazodidimethyl tetrafluoroborate, 3,4-methylenedioxybenzene 1-1 Mono-diazo-tetrafluoroborate or 4-fluoro-3-nitrobenzene difluorotrifluoromethylsulfonate.
  • Nitrite diagnostics eg N- (1-naphthyl) ethylenediamin 'dihydrochloride, 3-hydroxy-1,2,3,4-tetrahydro-7,8-benzoquinoline, or N— (1—Naphthylamino) One 3—Prono. Sunsolefonic acid.
  • Leukocyte diagnostic agent (M8) For example, indoxycarboxylic acid ester.
  • Specific gravity diagnostic agent (M 9): For example, BTB / methoxyethylene maleic anhydride copolymer or BTB polyacrylic acid.
  • Amylase diagnostics (M 10): For example, carboxymethyl starch remazolamide.
  • Ascorbic Acid Diagnostics (Mil): For example, Methylene Green Dutranolered, 2,6—Dichlorophene-Norenolein Defeno-Norhenium.
  • Salt diagnostics (Ml 2): For example, silver chloride 2,7_dichlorofluorescein.
  • Ketone body diagnostic agent For example, a two-mouthed pursidona triduniuni hydrate.
  • (M 0) is a reagent for diagnosing a disease using an antigen-antibody reaction, and is an antibody (y) immobilized on a support (hereinafter also referred to as (y)) or an antigen (X) (Hereinafter referred to as (X)) binds to (X) or (y) in the body fluid to form a conjugate, and the conjugate is further labeled with an antibody (M y) (hereinafter referred to as (M y)) or a labeled antigen (M x) (hereinafter also referred to as (M x)), and diagnosed based on a change in the color of the label, or as necessary, a coloring agent (d)
  • a diagnostic agent utilizing a so-called two-site sandwich measurement method based on the principle that the label can be colored to make a diagnosis based on the degree of color development can be given.
  • (X) and (y) include the antigens and antibodies described in US Pat. No. 5,073,485.
  • protein-related substances particularly CEA, TPA, polyamine, ⁇ 2-microglobulin, ⁇ - ⁇ , ⁇ -GTP, FDP, from the viewpoint of simplicity of measurement.
  • IgA IgA
  • microglobulin IgA
  • Different types of labels can be used depending on the diagnostic method. No. 5,073,485.
  • Preferred are chemiluminescent substances, and especially enzymes, latexes and metals.
  • the labeling substance is a chemiluminescent substance (eg, acrylonitrile ester, N-aminobutyl-N-ethylethylisonorenol (ABEI), etc.) And a method of reacting a solution of the prepared antigen with a sulfonate (Japanese Patent Application Laid-Open No. H05-340946).
  • chemiluminescent substance eg, acrylonitrile ester, N-aminobutyl-N-ethylethylisonorenol (ABEI), etc.
  • ABEI N-aminobutyl-N-ethylethylisonorenol
  • the labeling substance is an enzyme (for example, penoleoxidase, anorecalyl phosphatase, gnorecosoxidase, ⁇ -galactosidase, etc.), And ⁇ —succinimide 1— ( ⁇ —mice lime) After reacting cyclohexane 1 11 ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ And then fractionating it with a gel filtration column (Biochemical Experiment 27 Enzyme Labeling (Eiji Ishikawa: Gakkai Shuppan Center)).
  • an enzyme for example, penoleoxidase, anorecalyl phosphatase, gnorecosoxidase, ⁇ -galactosidase, etc.
  • the labeling substance is latex (for example, SBR latex)
  • 0.5 mg of the antibody is added to a buffer (pH 7.0 to 9.0), dissolved, and 10% latex particles (usually Add 0.5 mL of 0.3-0.5 ⁇ ), allow the reaction to proceed (for example, at 25 ° C for 1 hour), and then centrifuge (for example, 5 ° C, 100,000 rpm, (30 minutes), and put the sediment in a stabilizing agent (Block Ace (Dainippon Pharmaceutical Co., Ltd.)) to prepare 0.2% latex-labeled antibody.
  • a stabilizing agent Block Ace (Dainippon Pharmaceutical Co., Ltd.)
  • the labeling substance is a metal (for example, a method using gold colloid), it is reported by Lot & Geeuze (Eur. J. Cell Biol., 38, 87, 18985). There is a method that has been.
  • the binding amount and the binding ratio of the labeling substance are usually 70 to 100% based on the number of moles of the labeled antibody.
  • the label is an enzyme
  • (d) is required for coloring the label
  • (d) is a redox coloring agent [ortho-trizine, 1,2-phenylenediamine Fluorescent reagents [4—hydroxyphenylacetic acid, 3— (4—hydroxyphenyl) propionic acid, etc.], bioluminescent reagents [2—nitrophenyl' ⁇ — ⁇ -galactoside, noreciferi And its derivatives], and chemiluminescent reagents [luminol and its derivatives (such as phenylaminobutyl-ethylethyl sorbinol)] and the like.
  • the amount of (d) is usually 100 to 100,000,000 times based on the equivalent weight of the label.
  • Diagnosis according to (d) is performed by spraying, applying, dipping, or dropping a coloring aid to develop color, and observing or measuring the coloring intensity with a visual inspection device (spectroscopic analyzer, etc.).
  • reagents related to the color reaction such as oxidizing agents (peroxides, etc.) and enzymes (luciferase, glucose 16-phosphate dehydrogenase, etc.) are used simultaneously as color-forming aids. May be.
  • the weight ratio of the color-forming aid to (d) is preferably from 1 Z 1 to 100. Diagnostic absorber
  • the diagnostic absorbent of the present invention is composed of (A), (M) and, if necessary, other constituent materials.
  • the shape of the absorbent material is granular (spherical, granular, crushed, etc.), needle-like, flake-like, block-like, or agglomerated, in which primary particles are fused to each other. Needles, needles, flakes and aggregates are preferred.
  • the major axis and the minor axis are usually from 5 to 20 m, and preferably from 15 to: L O, ⁇ ⁇ ⁇ ⁇ ⁇ .
  • the absorbent of the present invention comprises ( ⁇ ) and ( ⁇ ) supported on it. Absorbents; and absorbents (M) and (A) supported on a support other than (A) or coated with a water-soluble or water-degradable coating material.
  • support means that (M) is also present on the surface of the support and, if necessary, inside the support, and “coating” means that (M) is present only inside the support. This is what you are doing.
  • the components to be supported or coated may be all of the components of (M), or some of the components of (M).
  • Absorbent materials in which (M) or a part of (M) is covered with a coating material are superior in that the storage stability can be improved compared to an absorbent material in which all of (M) is supported on a support. This is particularly preferred when (M) contains enzymes or peroxides.
  • Examples of the support other than (A) include the following fibers, granules, and chips.
  • the fibers include natural fibers, man-made fibers and synthetic fibers, mixtures thereof, and regenerated fibers thereof, and the following are exemplified.
  • Natural fiber [cotton, absorbent cotton, fibrous rattle, straw, grass charcoal, wool, microfibril, nocteria cellulose, hardwood bleached kraft pulp (LBKP), softwood bleached kraft pulp (NBKP), and other flapping pulp (E.g., waste materials from the manufacture of disposable diapers), artificial fibers [rayon and acetate, etc.], synthetic fibers [polyolefin fibers (Polyolefin fibers) Polyethylene fiber, polypropylene fiber, polyethylene / propylene composite fiber, etc.), polyester fiber (polyethylene terephthalate fiber and polyethylene terephthalate.polyethylene ethylene phthalate copolymer composite fiber, etc.), Polyolefin / polyester composite fibers (polyethylene'polyethylene terephthalate composite fiber and polypropylene'polyethylene terephthalate composite fiber, etc.), polyamide fibers (polyethylene terephthalate ethylene diamide fiber, polyisoterephthalic acid Ethy
  • natural fibers and synthetic fibers are preferred, and natural fibers are more preferred, particularly cotton, absorbent cotton, and fibrous rags, from the viewpoint that the strength of the absorbent is easily provided. Is waste from the production of pulp or disposable diapers.
  • the particulates include inorganic particulates and organic particulates, and inorganic particulates are preferable.
  • the composition of the inorganic particulate matter includes oxides (such as silicon oxide, aluminum oxide, iron oxide, titanium oxide, magnesium oxide, and zirconium oxide), calcium carbonate, kaolin, tanolek, mai power, and bentonite. Glass, powder, balloon, glass (powder and balloon), glass, graphite, metal (iron, copper, aluminum and gold, etc.), zeolite and aspect.
  • oxides such as silicon oxide, aluminum oxide, iron oxide, titanium oxide, magnesium oxide, and zirconium oxide
  • calcium carbonate such as calcium carbonate, kaolin, tanolek, mai power, and bentonite. Glass, powder, balloon, glass (powder and balloon), glass, graphite, metal (iron, copper, aluminum and gold, etc.), zeolite and aspect.
  • silicon oxide anodic aluminum oxide and titanium oxide
  • silicon oxide and oxidized oxide are preferred.
  • Inorganic particulates include porous inorganic particles (P 1) and non-porous inorganic single particles (P 2).
  • porous inorganic particles (P 1) examples include hollow, porous, petal, aggregated, and granulated particles.
  • the preferred Dav of the porous inorganic particles (P 1) is from 0.1 to: ⁇ ⁇ ⁇ ⁇ .
  • the preferred Dav of the non-porous inorganic single particles ( ⁇ 2) is 0.03 to 0.07 / m, and more preferably 0.01 to 0.054 ⁇ .
  • organic particulates examples include particulates made of natural, semi-synthetic or synthetic resins other than (ii).
  • Natural resins include mannan, starch, plant mucilage (arabia gum, guar gum, locust bean gum, carrageenan, etc.), seaweed-derived products (sodium alginate, agar (galatatan), etc.), and microbial mucilage. (Dextran, levan, etc.), protein (gelatin, casein, collagen, keratin, etc.), granular oataz, and the like.
  • Semi-synthetic resins include cellulosic derivatives such as viscose, methylcellulose, ethinoresenololose, hydroxysenorelose, canoleboximetinolenose, canolepo'ximetinolethynoresenorelose, nitrosenorelose, and cationizer.
  • thermoplastic resins polyamide resin, polyester resin, polyurethane resin, polyolefin resin, polystyrene resin, and acrylic resin
  • examples thereof include granular resin (including powder) of a thermosetting resin (epoxy resin, urea resin, phenol resin, and the like) or a resin such as a rill resin, a polyvinyl alcohol, or a polyether resin.
  • chips examples include pulp chips and chip-like sawdust.
  • the mode of loading of (M) may include physisorption, chemisorption or chemical bonding.
  • the method for supporting (M) on a support includes the following method. (1): Powder or liquid (M) is simply mixed with the support. (2): The support is impregnated with water of (M) or a mixed solvent solution of water and a hydrophilic organic solvent, and then dried.
  • heating preferably at 30 to 90 ° C
  • heating can promote adsorption or binding.
  • Absorbents obtained by physical adsorption by the above method (2) include, for example, (M) such as bromthymol blue, and water and a hydrophilic organic solvent (eg, methanol, ethanol, or acetate). Dissolve in a mixed solvent of pH or pH buffer to make a solution, add (A) to it, and gently stir at room temperature for a certain period of time (usually 1 to 120 minutes). After sufficient swelling, it can be obtained by drying under reduced pressure (40-60 ° C).
  • the preferred concentration of (M) based on the weight of the solution in the solution is usually 10 ppm to 50%, preferably 50 ppm ⁇ ! ⁇ 30%.
  • the weight ratio of the support Z (A) is preferably 95/5 to 55/45, more preferably 80/20 to 6 0/40.
  • the coating material may be a water-soluble or water-disintegrable polymer,
  • One or more amphiphilic substances which form micelles, vesicles or liposomes in aqueous solution can be used.
  • water-soluble or water-disintegrable polymer examples include the aforementioned seaweed-derived substances, proteins (gelatin, casein, etc.), and cellulosic derivatives (methylcellulose, ethynoresenorelose, hydroxy).
  • proteins such as sonololose and canoleboximetinolecellulose
  • solubilized starch such as sonololose and canoleboximetinolecellulose
  • solubilized starch such as solubilized starch, polyvinyl alcohol, and polyoxyalkylene oxide.
  • amphiphilic substance examples include known surfactants (for example, those described in US Pat. No. 4,331,447), as well as amino acids, phospholipids, and the like.
  • Biosurfactants such as bile salts, cyclodextrin derivatives, crown ether derivatives and the like.
  • a coating method a method of spraying or applying a coating material from the outside of (M) to harden it, and a method of coating (M) with a vesicle of the coating material in a solvent (water and Z or the above-mentioned hydrophilic organic solvent) are used. , Trapping in micelles or ribosomes and then removing the solvent.
  • a solvent water and Z or the above-mentioned hydrophilic organic solvent
  • the absorbent of the third embodiment is composed of (A) and (M) supported and / or coated, and includes a mixture of both, and a molded product thereof.
  • the method of mixing may be powder mixing, or liquid mixing in a solvent followed by solvent removal.
  • the absorbent of the present invention may further contain other constituent materials.
  • Other constituent materials include, for example, the aforementioned fibers, granules, chips, and the like.
  • additives include preservatives, fungicides, antibacterial agents, antioxidants, ultraviolet absorbers, coloring agents, fragrances, deodorants, and U.S. Patent No. 5,743,213.
  • preservatives include preservatives, fungicides, antibacterial agents, antioxidants, ultraviolet absorbers, coloring agents, fragrances, deodorants, and U.S. Patent No. 5,743,213.
  • One or more selected from the additives described in this document can be added.
  • the content of each component based on the weight of the absorbent of the present invention is as follows.
  • (A) is preferably at least 40%, more preferably at least 60%, especially at least 70%.
  • (A) is at least 40%, it is preferable in that a sufficient diagnostic speed and sufficient water return preventing property after water absorption can be maintained.
  • (M) (however, only those that are supported or coated) are preferably 1 pp ⁇ ! ⁇ 4%, especially 10 ppm force, etc. 1%.
  • the content of the support other than (A) is 0:! To 60%, preferably 3 to 50%.
  • additives are 0.0000 to 1: 10%, especially 0.0000 to 5%.
  • the content of (M) based on the weight of (A) is preferably 2.5 ppm to 10%, and more preferably 25 ppm. ⁇ 2.5%.
  • Examples of devices that can be used in (1) include a Nauta mixer, a Ribon mixer, a conical blender, a mortar mixer, and a universal mixer.
  • Examples of the method of adding water include a method of spraying water on a substrate, a method of blowing steam, and a method of absorbing moisture while maintaining the substrate at high humidity.
  • Monohydric alcohol in water as needed (E.g., methanol, ethanol, isopropyl alcohol), polyvalent ethanol (ethylene glycol, propylene glycol, glycerin, etc.) polyalkylene (2-4 carbon atoms) glycol (poly) Ethylene glycol, etc.), polyvinyl alcohol, the above-mentioned surfactants, etc. can be added for the purpose of improving the effect as a binder and the effect of water permeating into the base material and granulated material. it can.
  • the amount of water added depends on the type of substrate, but is usually 1 to 30%, preferably 2 to 15%, based on the weight of the substrate. When the amount of water to be added is 30% or less, the granulated material is not too soft, and the shape of the granulated material is less likely to be broken and the granulated materials are less likely to stick to each other. On the other hand, if the amount of water to be added is 1% or more, the granulation speed is high and a granulated product having a uniform shape is easily formed.
  • the diagnostic agent is (M 3)
  • a method of drying the absorbent under reduced pressure, adding a desiccant such as silica gel, and storing the absorbent in a bag may be used.
  • Examples of the method (2) include a method in which the base material is pressed into a pellet shape or the like in a mold having an appropriate shape and size, or a sheet shape, a rod shape, or a simple shape. Can be formed by pressure-molding into a block shape, and then cutting or pulverizing to the desired size and shape.
  • the pressure molding may be performed under a force S normally performed at normal temperature, a calo temperature (for example, 30 to 300 ° C.), or humidification (for example, 50 to 100% R.H.).
  • the pressure at the time of pressure molding is a force S which can be appropriately selected according to the type, particle size or properties of the base material, usually 1 to 3, 000 kg / cm 2 , preferably 10 to 2, 0 0 0 K g Z cm 2 .
  • Rolling press machines compacting press machine, pre-cutting press machine, etc.
  • piston press machine piston press machine
  • screw press machine Screw press machine
  • Pressure molding machine or perforated plate extrusion molding machine can be used.
  • the shapes of the absorbent obtained by molding as described above preferred are a sphere, a pellet, and a column.
  • the absorbent material of the first embodiment is for animal diagnosis
  • the absorbent material of the other embodiments is for animal and human diagnosis.
  • the absorbent of the present invention can be suitably used as it is as an absorbent for animal diagnosis, for example, an absorbent for pets, particularly cat sand. Diagnostic absorbent sheet
  • the diagnostic absorbent sheet for animals or humans composed of the absorbent material according to the first to fourth aspects of the present invention comprises the above absorbent material, and further comprises fibers, nonwoven fabric, paper and synthetic resin film. It is an absorbent sheet consisting of one or more members selected from the group.
  • absorbent sheets include single-layer sheets consisting of one sheet containing the absorbent material and multilayer sheets consisting of two to five or more layers.
  • the above-mentioned fibers can be used.
  • Non-woven fabrics include non-woven fabrics made of thermoplastic resin (for example, polyolefin resin, polyester resin or polyolefin-polyester copolymer), and paper made of cellulose fiber (Japanese paper and As the film, a film made of the above thermoplastic resin is preferably used.
  • thermoplastic resin for example, polyolefin resin, polyester resin or polyolefin-polyester copolymer
  • paper made of cellulose fiber Japanese paper and As the film, a film made of the above thermoplastic resin is preferably used.
  • the size of the absorbent sheet is usually an area of 2 5 ⁇ 2 5 0 0 cm 2 of rectangles, squares, and the like circular or oval, thickness 0. 5 ⁇ 5 0 mm, good or lay Ha :! ⁇ 20 mm.
  • the absorbent sheet is obtained by simultaneously mixing the above-mentioned absorbent material and fiber in an air stream.
  • Manufacture by combining and stacking fibers, mixing absorbent and fiber in advance and stacking in airflow, stacking absorbent on fiber, and stacking fiber can do.
  • An apparatus used in these methods includes, for example, a drum forming apparatus.
  • the basis weight of (A) contained in the absorbent sheet ⁇ content of (A) per unit area of the absorbent sheet ⁇ is 10 ⁇ :! OOO g Zm 2 is preferred, and more preferably 50 to 700 g Zm 2 .
  • the basis weight of the fibers contained in the absorbent sheet (excluding the fibers contained in the absorbent material) is 10 ⁇ :! OOO g Zm 2 is preferred, particularly preferably 50 to 70
  • the content of the absorbent in the absorbent sheet is preferably 40 to 99.9%, more preferably 62 to 80%, based on the weight of the absorbent sheet. . Within this range, the absorbent sheet can be made thinner.
  • the preferred structure of the absorbent sheet is a liquid-permeable front film (hereinafter abbreviated as OF) and a liquid-impermeable back film (hereinafter, referred to as “OF”) on both sides of the absorbent sheet.
  • (K 3) is preferable from the viewpoint of leakage of the absorbent from the absorbent sheet.
  • the OF is not particularly limited as long as bodily fluids that come into contact with the absorbent sheet easily penetrate and reach the internal absorbent material.
  • paper made of cellulose fiber such as Japanese paper and tissue paper
  • perforated film made of thermoplastic resin for example, polyolefin resin, polyester resin or polyolefin'polyester copolymer. It is preferably used.
  • the hole diameter of the apertured film is preferably 0.01 to 1 mm.
  • the thickness of the ⁇ F is preferably 5 to 500 // m, particularly preferably 20 to 750 111.
  • the preferred range of the material, pore diameter and thickness of CF is the same as that of OF.
  • the UF is not particularly limited as long as it can prevent the bodily fluid absorbed by the absorbent sheet from seeping out to the back surface.
  • a film made of the aforementioned thermoplastic resin or the like is used. Let's do it.
  • sheets made of polyolefin are preferred, more preferably sheets made of polyethylene, polypropylene or polyethylene / propylene, particularly preferably made of polyethylene. It is a sheet that can be obtained.
  • the thickness of U F is preferably in the same range as that of O F described above.
  • the absorbent sheet of the present invention can be suitably used, for example, as a urine sheet for dogs.
  • the diagnostic absorbent sheet according to the fifth embodiment of the present invention comprises the following (1) Is an absorbent sheet for diagnosis having (2) and a BZF separation layer (C) (hereinafter also referred to as (C)).
  • A Water-absorbent resin layer (hereinafter also referred to as (AL)) and layer (B 1) (hereinafter referred to as (B 1)) having (My) or (M x) supported on a support. U); or
  • (AL), (B1) and (C) are all layered, and these layers are laminated to form the absorbent sheet of the present invention.
  • (AL) is a mixture of (A) and the above-mentioned fiber, nonwoven fabric, paper, or the like, or a layered composite.
  • (B 1) in (1) above the labeled antibody-carrying layer (B My) (hereinafter also referred to as (BMy)) in which (My) is supported on the support and (M x) are supported on the support Labeled antigen-bearing layer (BM x) (hereinafter also referred to as (BM x)).
  • the preferred one is (BMy).
  • Examples of the material of the support constituting (B1) include the aforementioned fibers, paper (eg, filter paper), nonwoven fabric, synthetic resin, and the aforementioned natural resin.
  • the shape of the support may be any of sheet, powder, granule and fiber. Preference is given to sheets, powders and granules.
  • (B 2) and (C) are both layered, and these layers are stacked to form the absorbent sheet of the present invention.
  • (B 2) is obtained by using (A) as a support and carrying (My) or (M x) on (A).
  • (B) [Hereinafter, (B) including (B1) and (B2) is referred to as (B).
  • the dimensions are usually less than 30 x 30 cm, preferably less than IOXIOC m, especially from 3 x 3 cm to 1 x 1 cm, such as rectangles, squares and circles.
  • the preferred size and shape are different depending on the type and size of the human being or the animal, the viewpoint is that (M y) or (M x) must be completely released by body fluids.
  • the area is usually smaller than (AL) (for example, an area of 1 to 5 to 100), and is an area through which a single body fluid of the object sufficiently penetrates.
  • the thickness is usually between 0.1 and 10 mm, preferably between 0.1 and 3 mm.
  • the method for supporting (M y) or (M x) on a support includes water, a buffer solution (eg, pH 6.8, 0.02 M phosphate buffer), a hydrophilic organic solvent, and the like.
  • a buffer solution eg, pH 6.8, 0.02 M phosphate buffer
  • hydrophilic organic solvent e.g., alcohol-based solvents such as methanol and ethanol, ketone-based solvents such as acetone and methylethyl ketone, etc.
  • My a mixed solvent of a buffer and a hydrophilic organic solvent
  • (My ) Or (M x) is dissolved (100 ppb to 20% by weight), mixed with the support or impregnated in the support, and dried under reduced pressure or freeze-dried.
  • (M y) or (M x) supported on the support is generally released from the support at the same time as the body fluid permeates.
  • the amount of to be supported per unit area of the layered body of the support (M y) or (M x) is favored properly is 0 1 11 ⁇ (:. 111 2 ⁇ 1 0 0 111 8 0 11 2, and the Ku 1 O ng Z cm 2 ⁇ l 0 mg / cm Demel.
  • the ratio of (M y) or (M x) based on the weight of (A) is preferably 0. lppb ⁇ : 1,000 ppm, and more preferably 100 ppm from lppb force. ppm.
  • (B) is preferably in the range of 0.01 to 3 mL / Z, particularly preferably in the range of 0.05 to 2.
  • the water permeability can be measured by the following method.
  • the permeability rate is calculated by the following formula (3).
  • (C) is a conjugate formed by an antigen-antibody reaction between (M y) or (M x) and (X) or (y) in a body fluid [hereinafter, referred to as a labeled conjugate. (M xy)] and unreacted (M y) or (M x).
  • (C) has a BZF separation layer (C 1) (hereinafter referred to as “BZF separation layer”) having an immobilized antigen (f X) or an immobilized antibody (fy) that reacts with unreacted (M y) or (M x). (Also referred to as (C 1)), and a BZF separation layer (C 2) (hereinafter also referred to as (C 2)) that separates (M xy) depending on the pore size of the separation layer.
  • BZF separation layer an immobilized antigen (f X) or an immobilized antibody (fy) that reacts with unreacted (M y) or (M x).
  • Also referred to as (C 1) Also referred to as (C 1)
  • C 2 BZF separation layer
  • CI usually contains (X) or (y) of the same type as (X) or (y) in the body fluid to be diagnosed, either on the surface or inside the support. Has been immobilized.
  • the shape and material of the support those similar to the support described in the above (B1) or (B2) are exemplified.
  • Preferred examples thereof include sheet-like materials such as paper (eg, filter paper), and the like. It is a sheet made of granular water-absorbent resin and pulp.
  • the amount of (X) or (y) immobilized on (C 1) is preferably 0.1 g / cm 2 to 500 mg / c per unit surface area of the layered material of the support. lng / cm 2 to 250 mg Z cm 2, which is larger than the amount of (M x) or (My) carried on (B) [for example, the amount carried on (B) 1.2 to 10 times, preferably 1.5 to 5 times).
  • a method for immobilizing (X) or (y) on the support there are a method of physically adsorbing and a method of bonding by a chemical reaction.
  • physical adsorption include the method of physically adsorbing (X) to a support having high adsorptivity to protein, such as a cellulose ester (sheets such as cellulose acetate), and a chemical reaction.
  • a support eg, a sheet of nitrocellulose
  • N-sulfosuccinimidyl-41 Metalmethyl
  • the (C 2) is a sheet or film, having a molecular weight cut off smaller than the molecular weight of S (MX y), and is an unreacted (X) or (y) molecule. Those larger than the amount are preferred.
  • the molecular weight cut off of (C 2) is preferably 100,000 to 300,000, especially 30,000 to 200,000, and (C 2) Difference between the molecular weight of the fraction and the molecular weight of (M xy) It is preferable that the absolute value of the difference between the molecular weight of the fraction and the molecular weight of the unreacted (X) or (y) is 5,000 or more.
  • the water permeation rate in (C) is related to the antigen-antibody reaction rate in the absorbent sheet. For example, if (C) is placed at the bottom of the absorbent sheet and the sample liquid is dropped on the top, the lower the water permeation rate of (C), the lower the (X) or (y) force S (fy) or The number of times that (fx) can be contacted increases, the reaction rate increases, and the resolution in (C) increases. However, if the water permeation speed becomes extremely slow, the leaching speed of the separated liquid will decrease, and the time required for measurement will increase.
  • (C) preferably has a water permeation rate (25 ° C, 1 atm) of 0.01 to 3 mLZ, especially 0.05 to 2.5 mLZ. Same as (B) above). Within this range, BF separation is easily performed and the diagnostic speed is high.
  • the absorber of the present invention may further comprise a color former layer (D) (hereinafter also referred to as (D)), OF and Z or UF.
  • D color former layer
  • Examples of (d) carried on (D) include those described above, and examples of the support include those having the same shape and material as those exemplified in (B1) or (C) above. Is exemplified. The same goes for the preferred ones.
  • Loading amount of (d) is per unit surface area of the support, favored properly is 1 0 0 fmo 1 / cm 2 ⁇ 5 0 0 mm o 1 / cm ", and Ku in 1 pmo 1 / cm ⁇ 5 0 mmo 1 / cm.
  • Examples of the method of supporting the same include the same method as the method of supporting (M y) or (M X) on the substrate as exemplified in (C 1) above.
  • Diagnosis by (D) is color development after reaching (My) or (X)
  • the reaction is performed, and the color intensity is observed or measured with a visual inspection device (such as a spectroscopic analyzer).
  • the color-forming reaction is carried out by carrying all reagents involved in the color-forming reaction on (D) and developing without post-treatment (dl), (D) to (M y) or (X) after reaching (X).
  • Either method (d 2), in which a part of the relevant reagents are added later to develop color, may be used.
  • the above-described color-forming auxiliary may be supported simultaneously.
  • the amount of the color-forming aid is preferably the same weight as the amount of (d) carried, and 1/100.
  • (D) may be taken out and a coloring reaction may be carried out by spraying, applying, dipping or dripping a coloring aid. Observation or measurement of the coloring intensity may be performed with (D) after the coloring reaction fixed at the original position, or may be taken out and performed.
  • the same OF and UF as described above can be used as the OF and UF used as needed.
  • the order of the essential constituent materials (B) and (C) in the absorbent sheet according to the fifth embodiment of the present invention is usually such that the side to which the body fluid is supplied (hereinafter referred to as the body fluid side) ) Is arranged, and (C) is arranged outside. Also, the position of (AL) is preferably on the fluid side of (B), between (B) and (C), outside of (C), and in combination of two or more of these positions.
  • the absorbent sheet according to the fifth embodiment of the present invention is obtained by laminating each layer of (AL), (B), (C) and (D) if necessary, in the above order, and then obtaining the desired size. It can be manufactured by cutting, or by producing layers of the desired size and shape for each layer, and then laminating or bonding each layer.
  • the absorbent sheet shown in FIG. 1 is composed of a B / F separation layer (C) having a water-absorbent resin layer (AL), a layer (B1) supporting a labeled antibody (My), and an immobilized antigen (fx). 1).
  • the concentration of (M xy) exiting through (C 1) is correlated with the concentration of (X) in (U). Therefore, the diagnosis can be made by measuring the concentration of (Mxy) by the colorant method or the like.
  • the absorbent sheet shown in FIG. 4 is composed of the layer of FIG. 1 described above, and further comprises a color former layer (D), a front film (OF) and a back film (UF).
  • D color former layer
  • OF front film
  • UF back film
  • the absorptive sheet shown in FIG. 5 includes a layer (B 2) carrying the labeled antibody (My) on the water-absorbent resin (A), a layer (C I) having the immobilized antigen (fx),
  • the absorbent sheet shown in FIG. 6 has a configuration using (C 2) which separates according to the size of the pore diameter instead of (C 1) in the configuration of FIG.
  • the diagnostic absorbent sheet of the present invention can be used as it is as an excrement disposal material.
  • a pellet-shaped excrement disposal material composed of a water-absorbent resin and a fibrous material on an absorbent sheet (for example, one described in Japanese Patent Application Laid-Open No. Hei 7-325756) or sand, etc.
  • a known excrement disposal material made of a material may be laminated or sprayed. Diagnostic absorbent articles
  • the disposable diaper, the pet toilet, the simple toilet, the portable toilet, the sanitary napkin, the incontinence pad and the wound sheet according to the present invention may be any one of the above-mentioned absorbent or absorbent sheets, trays, It is composed of a bag, a nose or a bottle, and is a diagnostic absorbent article.
  • the pet toilet for the present invention is (1) a cat sand placed on a tray or the like, (2) a urine sheet placed on a tray vinyl sheet, A combination of (1) and (2) (a urine sheet is laid on the tray, a net-shaped tray is placed on top of it, and cat sand is placed on top of it. Composite type toilet).
  • Paper mummets include those in which an absorbent body is provided with gathers or the like to enhance the adhesion to the abdomen, waist, thighs, or crotch, and a mounting tape or the like to prevent slipping.
  • the material and type of the gather and the mounting tape are not particularly limited, and known materials used for conventional paper mats can be used.
  • Diagnosis using an absorbent sheet or absorbent article can be performed by checking the color change by opening the film with a structure that can open and close (OF) or a part of (UF) as necessary. Diagnose.
  • OF open and close
  • UF part of
  • the absorbent sheet and absorbent article of the present invention can be used for terrestrial animals and animals or humans, and are bred, for example, for pets and livestock. It can be suitably used for animals, especially mammals and birds.
  • pets include dogs, cats, egrets, monkeys, nomsters, fillets, raccoons and risks, and livestock such as horses, horses, hibiscus, and pigs.
  • livestock such as horses, horses, hibiscus, and pigs.
  • other bred mammals include wild boar, fox, deer, camel, zodia and kirin.
  • pets include canaries, parakeets, notes, wild birds and birds, and other bred birds include birds, ducks, fish, hawks and crows. can give.
  • Example 1 Absorbent for measuring specific gravity of urine (Absorbent of 1 'embodiment)
  • a standard color sample was prepared by adding 25 g of each standard urine to 5 g of the above-mentioned absorbent (absorbent one hour after preparation). The sample with a specific gravity of 1.005 was green, and the yellow color increased as the specific gravity increased. The color samples were stored in a glass bottle with a volume of 70 mL with a lid (hereinafter all color samples were stored in the same container). Measurement of urine specific gravity:
  • the color of the sample is between the color samples of specific gravity 1.015 and specific gravity 1.020, the color tone was observed and the specific gravity was determined in increments of 0.001. . The judgment was made by three people and the average value was taken as the specific gravity.
  • the color development speed was visually confirmed from the time urine was added to the time color development was completed, and the time required was measured.
  • the absorbent was allowed to stand in an open state, and the time required for the specific gravity reading to change by 0.010 was measured to evaluate the color development continuity.
  • Urine test paper “Pr e t e s t” (W ako P ur eCh e m i c a
  • the color development speed was visually checked from the time urine was added to the time color development was completed, and the required time was measured. .
  • the absorbent was allowed to stand in an open state, and the time required for the sugar to change by one or more steps from the judgment value of the sugar after the color development was measured to evaluate the color development continuity.
  • the glucose concentration measured with the absorbent of the comparative example and the glucose concentration measured with the urine test strip only match 6 out of 8 samples, and the accurate absorption of glucose cannot be measured with the absorbent of the comparative example. I understood.
  • the glucose concentration was measured using the absorbent stored at 5 ° C or 50 ° C for 3 months in the same manner as in Example 2 except that the absorbent of the comparative example was used. Was measured. The results are shown in Table 2-6,
  • the sialicbumin was dissolved in protein-negative (1) cysteine urine using "Pretest" to prepare standard urine of 15, 30, 100, and lOOOOmgZdL.
  • the standard urines were protein (sat) urine, protein (+) urine, protein (2+) urine, and protein (3+) urine.
  • a color sample was prepared by adding 25 g of each standard urine to 5 g of the above absorbent material. When protein was present, the color changed from yellow to green, and the greenness increased as the protein concentration increased. Protein measurement:
  • a sample in which 5 g of the above absorbent material was added to 25 g of each of the eight urine samples was visually judged by comparing the protein concentration with the above five stages in comparison with a color sample.
  • the protein concentration measured with the absorbent of the present invention and the protein concentration measured with the urine test paper were the same in eight samples, and the protein concentration was measured with the absorbent of the present invention. It was proved that it could be set. Table 3 shows the results. Comparative Example 3;
  • the protein concentration measured with the absorbent material of the comparative example and the protein concentration measured with the urine test paper matched only 5 out of the 8 samples, and the urine which was negative on the urine test paper became a false positive. In some cases, false positive urine was determined to be positive. It was found that the absorbent of the comparative example could not measure protein concentration with high reliability.
  • Dissolve 1 g of peroxide in mouth with 25 g of methanol add 5 g of silica powder having a Dav of 3600 ⁇ to Q, and use a vacuum drier at 25 ° C and 0.0 After drying at 5 MPa for 1 hour, a silica powder supporting cumene peroxide was prepared. Thereafter, 50 g of water was added, stirred and sufficiently dispersed, and 15 g of water-soluble starch (“Pine Flow S” manufactured by Matsutani Chemical Co., Ltd.) was added. In addition, the operation of adding 5 g of methanol and stirring for 1 minute was repeated 10 times. Then, a total of 50 g of methanol was added.
  • the human hemoglobin obtained by removing the plasma part from normal human blood was dissolved in human urine with negative occult blood ( ⁇ ) by “Pretest” to obtain 0.06, 0.15, 0.75.
  • a standard urine of mg Z d L was prepared.
  • the standard urine was occult blood (+) urine, occult blood (2+) urine, and occult blood (3+) urine.
  • a color sample was prepared by adding 25 g of each standard urine to 5 g of the above-mentioned absorbent (absorbent one hour after preparation). As the occult blood concentration increased, the bluish color increased.
  • the occult blood concentration was divided into the above four stages as compared with the standard color sample. It was visually determined. The determination was made in the same manner as in Example 2.
  • the occult blood concentration of each of the above eight human urine samples was measured using “Pretest”, and four-step judgment was performed.
  • the occult blood concentration measured with the absorbent of the present invention and the occult blood concentration measured with the urine test paper were in agreement with eight samples, demonstrating that the occult blood concentration can be measured with the absorbent of the present invention.
  • the results are shown in Table 4-1.
  • the color development speed was visually checked from the time urine was added to the time color development was completed, and the required time was measured.
  • the dry feeling was evaluated by the following method. Place absorbent paper (5 cm x 5 cm) on a polyethylene film (5 cm x 5 cm), spread the absorbent after urine addition on it to a height of 2 mm, and place it on it. Polyethylene finolem (5 cm x 5 cm) and polypropylene non-woven fabric (5 cm x 5 cm) were placed in this order (total thickness of 2.5 mm). The dry feeling was evaluated from the top of the non-woven fabric by touch feeling evaluation. Three people evaluated the following five-point scale to determine the average value.
  • Rating 2 The liquid feels wet when touched lightly, and floats when strongly touched. Rating 3; Touch slightly to feel slightly damp, touch strongly to feel wet. Rating 4: There is no damp feeling when touched lightly, but damp feeling when strongly touched. Rating 5: No feeling of damp even if strongly touched, good feeling of try. Table 41
  • a color sample was prepared in the same manner as in Example 4 except that the absorbent was used, and the occult blood concentration of human urine was prepared in the same manner as in Example 4 except that the absorbent was used. The degree was measured.
  • the occult blood concentration measured by the measurement method of Example 4 and the occult blood concentration measured by the urine test strip were the same in eight samples, but the dry feeling was inferior to that of the absorbent material of the example. It turned out. The results are shown in Table 4-2.
  • FIG. 7 is a cross-sectional view of a part of the absorbent sheet of Example 5; Is as follows.
  • A Water-absorbent resin layer
  • 12 g of Aquapearl DS-150 T and 12 g of cotton wool of Japanese Pharmacopoeia (Kawamoto Sangyo Co., Ltd.) are homogeneous in appearance.
  • the mixture was defibrated by hand approximately 500 times while mixing. After that, the defibrated mixture was spread to a size of 15 cm x 45 cm, and then heated using a heater plate press (Model No. N 408 — 0 0) manufactured by NPA System Co., Ltd. Pressed at 8 ° C. for 30 seconds at 8 kg Z cm 2 .
  • a heater plate press Model No. N 408 — 0 0
  • Labeled antibody carrying layer (B1) (hereinafter referred to as (B1)): Filter paper (No.2, manufactured by Advantech, cut into 5 mm x 5 mm) After impregnation (25 ° C, 30 minutes) with the phosphate buffer solution of y)), filter paper was taken out and dried (25 ° C, 2 hours, 1755 mmHg).
  • the concentration of (My) in the phosphate buffer was 300 ⁇ g Zm1, pH 7, 0, containing 0.1% bovine serum albumin.
  • Labeled antibody (My): Peroxidase-labeled anti-32-microglobulin polyclonal antibody.
  • My was prepared using anti-] 32-microglobulin polyclonal antibody (manufactured by Dako Japan) and horseradish peroxidase (manufactured by Toyobo Co., Ltd.). 'Ishika, et al .; J. Biochem, Vol. 92 (1992) 14 14 13 14 24].
  • BZF separation layer (C 1) (hereinafter also referred to as (C 1)): A membrane filter (mixed cellulose ester type, pore size 0.3 ⁇ , diameter 47 mm, manufactured by Advantech) is used as antigen ⁇ 2 — A solution of microglobulin (manufactured by SIPAC) in a phosphate buffer (antigen concentration 5; Ug Zml, pH 7, 0.1% bovine serum (Including Bumin) at 25 ° C for 1 hour, then take out the sheet and dry (3 hours at 25 ° C and 1 755 mmHg).
  • phosphate buffer antigen concentration 5; Ug Zml, pH 7, 0.1% bovine serum (Including Bumin)
  • Coloring agent layer (D) (hereinafter also referred to as (D)): Filter paper (N 0.2, manufactured by Advantech, cut to 2 Omm in diameter) One sheet of o-trimethyl After immersion in a ethanol solution (0.1% (wZw)) at 25 ° C for 5 minutes, the filter paper was taken out and dried (25 ° C, —75 mmHg for 30 minutes). .
  • Back film (U F) (also referred to as (U F)): Polypropylene finolem (15 cm X 45 cm) with a thickness of 40 ⁇ .
  • (AL) is placed under OF
  • (B1) and (C1) are placed in this order so that it is located at the center of (AL), and a hole with a diameter of 20 mm is placed at the center.
  • (UF) With the open, place the (D) in this hole, and then apply double-sided tape with a width of 5 mm along the circumference. UF).
  • the sides of the above layers (15 cm x 45 cm quadrilateral) were hot-pressed with a width of 1 cm each to obtain a diagnostic absorber.
  • Color-forming aid solution A solution in which phosphoric acid-monocitrate buffer (pH 5.0) contains 0.02% by weight of hydrogen peroxide.
  • Tested samples Twenty samples of human urine were obtained immediately before the test.
  • Test method The sample (80 ml) was placed in a 200 ml beaker and allowed to flow down at a speed of 5 ml Z seconds while gradually tilting the beaker so that the mouth was in contact with the absorbent sheet.
  • the measurement procedure is as follows.
  • test method Twenty samples of human serum were obtained. The test was performed by diluting serum 20-fold with phosphate buffer (0.02 M, pH 7.0) as a test sample. Test method:
  • Table 6 shows the measurement results obtained by the method using the absorbent sheet of the present invention and the conventional method.
  • Diagnosis using the absorbent sheet or the absorbent article for diagnosis of the present invention allows the above-mentioned changes in the physical condition of animals and humans, the presence or absence of pregnancy, the presence or absence of disease, and the progress of the disease to be confirmed.
  • the target diseases and changes in physical condition include cancer (stomach cancer, colorectal cancer, lung cancer, liver cancer, thyroid cancer, breast cancer, uterine cancer, urinary tract cancer, ovarian cancer, prostate cancer, etc.) , Infectious diseases, steroid therapy, renal urinary tract tumors, asymptomatic bacteriosis, antibiotic administration and hormonal abnormalities.

Abstract

L'invention concerne un agent absorbant de diagnostic contenant une résine (A) absorbant l'eau et un agent de diagnostic, par exemple un agent de diagnostic de pH, un agent de diagnostic de protéine, un agent de diagnostic de glucose ou un agent de diagnostic de sang occulte. Ladite résine (A) contient un ou plusieurs monomères sélectionnés dans le groupe comprenant des amides d'acide monocarboxylique aliphatique non saturé, des oxydes d'alkylène et des produits alkylés et des produits éthérifiés d'alkyle de ceux-ci, avec éventuellement un ou plusieurs monomères sélectionnés dans le groupe comprenant des monomères anioniques non saturés, des monomères cationiques non saturés et des sels de ceux-ci comme monomère(s) essentiel(s) et avec une équivalence acide/base de 2 meq/g ou moins déterminée par titrage par neutralisation à un pH de 4 à 9; et une feuille absorbante de diagnostic d'animaux ou d'humains faite dudit agent absorbant, d'une fibre, d'un tissu non tissé, de papier, d'un film résineux synthétique, etc..
PCT/JP2003/008814 2002-07-12 2003-07-10 Agent absorbant de diagnostic et article absorbant WO2004008139A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002204929 2002-07-12
JP2002-204929 2002-07-12
JP2002364243 2002-12-16
JP2002-364243 2002-12-16

Publications (1)

Publication Number Publication Date
WO2004008139A1 true WO2004008139A1 (fr) 2004-01-22

Family

ID=30117460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/008814 WO2004008139A1 (fr) 2002-07-12 2003-07-10 Agent absorbant de diagnostic et article absorbant

Country Status (1)

Country Link
WO (1) WO2004008139A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107247118A (zh) * 2017-06-29 2017-10-13 国家电网公司 一种吸附剂水分吸附速率测定装置及方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5346199B2 (fr) * 1975-03-27 1978-12-12
JPH11295306A (ja) * 1998-04-14 1999-10-29 Biseiken:Kk 尿検査用試験材並びにこれを用いた健康チェック材及び健康チェック方法
JP2001033457A (ja) * 1999-07-26 2001-02-09 Fuji Photo Film Co Ltd 乾式分析方法及び乾式分析要素
JP2001059845A (ja) * 1999-08-24 2001-03-06 Fuji Photo Film Co Ltd 乾式分析方法及び乾式分析要素
JP2001083152A (ja) * 1999-09-16 2001-03-30 Fuji Photo Film Co Ltd 乾式免疫分析方法及び乾式分析要素
JP2001289845A (ja) * 2000-04-10 2001-10-19 Sanwa Newtec Co Ltd 尿検査おむつ

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5346199B2 (fr) * 1975-03-27 1978-12-12
JPH11295306A (ja) * 1998-04-14 1999-10-29 Biseiken:Kk 尿検査用試験材並びにこれを用いた健康チェック材及び健康チェック方法
JP2001033457A (ja) * 1999-07-26 2001-02-09 Fuji Photo Film Co Ltd 乾式分析方法及び乾式分析要素
JP2001059845A (ja) * 1999-08-24 2001-03-06 Fuji Photo Film Co Ltd 乾式分析方法及び乾式分析要素
JP2001083152A (ja) * 1999-09-16 2001-03-30 Fuji Photo Film Co Ltd 乾式免疫分析方法及び乾式分析要素
JP2001289845A (ja) * 2000-04-10 2001-10-19 Sanwa Newtec Co Ltd 尿検査おむつ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107247118A (zh) * 2017-06-29 2017-10-13 国家电网公司 一种吸附剂水分吸附速率测定装置及方法

Similar Documents

Publication Publication Date Title
KR100239949B1 (ko) 연속 다공성 매트릭스에 혼입된 공유 반응성 입자(covalently reactive particles incorporated in a continuous porous matrix)
TW390806B (en) Breathable disposable absorbent articles
RU2568565C2 (ru) Одноразовые подгузники
TWI231761B (en) Superabsorbent-containing composites
TW515708B (en) Absorbent article
TWI594738B (zh) Absorber and absorbent article using the same
CZ213593A3 (en) Absorption structure and absorption articles
TWI412382B (zh) Deodorant particles
JP3878581B2 (ja) 診断用吸収材および吸収性物品
BRPI0920200B1 (pt) Processo para a produção de um gel de polímero superabsorvente com finos polímeros superabsorventes reciclados, processo para a produção de polímero superabsorvente particulado fundamento
KR19990067595A (ko) 흡수성 복합체 및 이로 이루어진 일회용 흡수성 가먼트
JPH11501362A (ja) 抗菌剤でコートされたヒドロゲル形成吸収ポリマー
JPH0779965B2 (ja) 吸収体
JPH09509591A (ja) 改良された吸収特性を有する吸収性材料およびその製造方法
BR112013024336B1 (pt) Composição de polímero superabsorvente particulada, processo para a produção de uma composição polimérica superabsorvente particulada e artigo absorvente
WO2012120812A1 (fr) Tampon absorbant
JPH06502911A (ja) 固相沈澱アッセイ装置および方法
GB1562505A (en) Absorbent laminate
ES2936111T3 (es) Pieza de prueba inmunocromatográfica para extracción y medición de antígeno de cadena de azúcar, que es capaz de prevenir reacción no específica
TWI605803B (zh) Absorber and absorbent article using the same
TW406013B (en) Absorbent structure comprising a highly absorbent polymer, and an absorbent article comprising the absorbent structure
JP2018086148A (ja) 吸収性物品
JPH11506038A (ja) 凝固剤を含有する吸収性製品
WO2004008139A1 (fr) Agent absorbant de diagnostic et article absorbant
JP3008181B2 (ja) 吸水材用表面材及びそれを用いた体液吸収材

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase